Loading…

35 Prescribing behavior of analgosedatives for extremely premature neonates: a retrospective analysis

IntroductionManaging pain in extremely premature (EP) neonates is complex, and protocols at institutions often lack tailored advice for different indications or patient characteristics, increasing the risk of inadequate pain management. This study aims to examine clinician prescribing behavior, iden...

Full description

Saved in:
Bibliographic Details
Published in:BMJ paediatrics open 2024-08, Vol.8 (Suppl 6), p.A17-A17
Main Authors: Abdouni, Samir El, van den Bosch, GE, van Rosse, F, Simons, SHP, Flint, RB
Format: Article
Language:English
Subjects:
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A17
container_issue Suppl 6
container_start_page A17
container_title BMJ paediatrics open
container_volume 8
creator Abdouni, Samir El
van den Bosch, GE
van Rosse, F
Simons, SHP
Flint, RB
description IntroductionManaging pain in extremely premature (EP) neonates is complex, and protocols at institutions often lack tailored advice for different indications or patient characteristics, increasing the risk of inadequate pain management. This study aims to examine clinician prescribing behavior, identify areas for improvement, and suggest modifications to existing protocols, which enables the improvement of analgosedative therapy for EP neonates.MethodologyIn this single center, retrospective study, we analyzed data from all EP neonates admitted to our NICU between 2017 and 2021, comparing baseline characteristics and drug administration data.ResultsOf the 2633 neonates admitted to the NICU, 10.2% (n=268) was EP at the time of admission. Of these, 53.4% (n=143) received analgosedative therapy. ‘Pain’ was the most common therapeutic indication (51.8%). Morphine, fentanyl, and acetaminophen were prescribed to more than half of the patients. Over 90% of patients received their analgosedative drugs exclusively intravenously (IV). Morphine and midazolam were mainly administered via continuous infusion, while fentanyl and acetaminophen were mostly given as bolus. During the initiation of continuous infusion, loading doses were administered for morphine and midazolam in 67.6% and 58.6% of cases, respectively. At dose escalation, these percentages decreased to 39.8% and 33.3% for morphine and midazolam, respectively. Morphine continuous infusion patients who always received a loading dose required a lower median dosage at 24 hours (5.0 mg/kg/hr) than those who didn’t (11.0 mg/kg/hr). This trend was not observed for midazolam (see table 1).ConclusionThe observed higher dosages required by EP neonates who did not receive a loading dose highlights the need for a critical evaluation of the use of loading doses during the initiation and dose escalation of continuous infusions, with the aim of reducing pain in this vulnerable population.
doi_str_mv 10.1136/bmjpo-2024-ESDPPP.35
format article
fullrecord <record><control><sourceid>proquest_9YT</sourceid><recordid>TN_cdi_proquest_journals_3086429417</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3086429417</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1155-62ee5a5f1bf06fd8aac153cc3553aa761644af71eb5af1b0430a6092beb5feea3</originalsourceid><addsrcrecordid>eNpFkM1KAzEUhYMgWGrfwEXA9dT8TDKNO6n1BwoOqOvhZnpTp7STMZkW3bnxRX0S01ZwdeDw3cPlI-SCszHnUl_ZzarzmWAiz2bPt2VZjqU6IQMhjclMUYgzMopxxRjjZmJyJQZkKdXP13cZMNahsU27pBbfYNf4QL2j0MJ66SMuoG92GKlLNX70ATe4_qRdSui3AWmLvoUe4zUFGrAPPnZY708OC5-xiefk1ME64ugvh-T1bvYyfcjmT_eP05t5ZjlXKtMCUYFy3Dqm3WICUHMl61oqJQEKzXWegys4WgUJYrlkoJkRNhUOEeSQXB53u-Dftxj7auW3IT0RK8kmOhcm50Wi2JFKwv4Bzqq9xepgsdpbrI4WK6nkL5YPbPI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3086429417</pqid></control><display><type>article</type><title>35 Prescribing behavior of analgosedatives for extremely premature neonates: a retrospective analysis</title><source>BMJ Open Access Journals</source><creator>Abdouni, Samir El ; van den Bosch, GE ; van Rosse, F ; Simons, SHP ; Flint, RB</creator><creatorcontrib>Abdouni, Samir El ; van den Bosch, GE ; van Rosse, F ; Simons, SHP ; Flint, RB</creatorcontrib><description>IntroductionManaging pain in extremely premature (EP) neonates is complex, and protocols at institutions often lack tailored advice for different indications or patient characteristics, increasing the risk of inadequate pain management. This study aims to examine clinician prescribing behavior, identify areas for improvement, and suggest modifications to existing protocols, which enables the improvement of analgosedative therapy for EP neonates.MethodologyIn this single center, retrospective study, we analyzed data from all EP neonates admitted to our NICU between 2017 and 2021, comparing baseline characteristics and drug administration data.ResultsOf the 2633 neonates admitted to the NICU, 10.2% (n=268) was EP at the time of admission. Of these, 53.4% (n=143) received analgosedative therapy. ‘Pain’ was the most common therapeutic indication (51.8%). Morphine, fentanyl, and acetaminophen were prescribed to more than half of the patients. Over 90% of patients received their analgosedative drugs exclusively intravenously (IV). Morphine and midazolam were mainly administered via continuous infusion, while fentanyl and acetaminophen were mostly given as bolus. During the initiation of continuous infusion, loading doses were administered for morphine and midazolam in 67.6% and 58.6% of cases, respectively. At dose escalation, these percentages decreased to 39.8% and 33.3% for morphine and midazolam, respectively. Morphine continuous infusion patients who always received a loading dose required a lower median dosage at 24 hours (5.0 mg/kg/hr) than those who didn’t (11.0 mg/kg/hr). This trend was not observed for midazolam (see table 1).ConclusionThe observed higher dosages required by EP neonates who did not receive a loading dose highlights the need for a critical evaluation of the use of loading doses during the initiation and dose escalation of continuous infusions, with the aim of reducing pain in this vulnerable population.</description><identifier>EISSN: 2399-9772</identifier><identifier>DOI: 10.1136/bmjpo-2024-ESDPPP.35</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd</publisher><subject>Analgesics ; Fentanyl ; I) Posters ; Morphine ; Newborn babies ; Pediatrics</subject><ispartof>BMJ paediatrics open, 2024-08, Vol.8 (Suppl 6), p.A17-A17</ispartof><rights>Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://bmjpaedsopen.bmj.com/content/8/Suppl_6/A17.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://bmjpaedsopen.bmj.com/content/8/Suppl_6/A17.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,55350,77660,77686</link.rule.ids><linktorsrc>$$Uhttps://bmjpaedsopen.bmj.com/content/8/Suppl_6/A17.1.full$$EView_record_in_BMJ_Publishing_Group_Ltd$$FView_record_in_$$GBMJ_Publishing_Group_Ltd</linktorsrc></links><search><creatorcontrib>Abdouni, Samir El</creatorcontrib><creatorcontrib>van den Bosch, GE</creatorcontrib><creatorcontrib>van Rosse, F</creatorcontrib><creatorcontrib>Simons, SHP</creatorcontrib><creatorcontrib>Flint, RB</creatorcontrib><title>35 Prescribing behavior of analgosedatives for extremely premature neonates: a retrospective analysis</title><title>BMJ paediatrics open</title><addtitle>bmjpo</addtitle><addtitle>BMJ Paediatrics Open</addtitle><description>IntroductionManaging pain in extremely premature (EP) neonates is complex, and protocols at institutions often lack tailored advice for different indications or patient characteristics, increasing the risk of inadequate pain management. This study aims to examine clinician prescribing behavior, identify areas for improvement, and suggest modifications to existing protocols, which enables the improvement of analgosedative therapy for EP neonates.MethodologyIn this single center, retrospective study, we analyzed data from all EP neonates admitted to our NICU between 2017 and 2021, comparing baseline characteristics and drug administration data.ResultsOf the 2633 neonates admitted to the NICU, 10.2% (n=268) was EP at the time of admission. Of these, 53.4% (n=143) received analgosedative therapy. ‘Pain’ was the most common therapeutic indication (51.8%). Morphine, fentanyl, and acetaminophen were prescribed to more than half of the patients. Over 90% of patients received their analgosedative drugs exclusively intravenously (IV). Morphine and midazolam were mainly administered via continuous infusion, while fentanyl and acetaminophen were mostly given as bolus. During the initiation of continuous infusion, loading doses were administered for morphine and midazolam in 67.6% and 58.6% of cases, respectively. At dose escalation, these percentages decreased to 39.8% and 33.3% for morphine and midazolam, respectively. Morphine continuous infusion patients who always received a loading dose required a lower median dosage at 24 hours (5.0 mg/kg/hr) than those who didn’t (11.0 mg/kg/hr). This trend was not observed for midazolam (see table 1).ConclusionThe observed higher dosages required by EP neonates who did not receive a loading dose highlights the need for a critical evaluation of the use of loading doses during the initiation and dose escalation of continuous infusions, with the aim of reducing pain in this vulnerable population.</description><subject>Analgesics</subject><subject>Fentanyl</subject><subject>I) Posters</subject><subject>Morphine</subject><subject>Newborn babies</subject><subject>Pediatrics</subject><issn>2399-9772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpFkM1KAzEUhYMgWGrfwEXA9dT8TDKNO6n1BwoOqOvhZnpTp7STMZkW3bnxRX0S01ZwdeDw3cPlI-SCszHnUl_ZzarzmWAiz2bPt2VZjqU6IQMhjclMUYgzMopxxRjjZmJyJQZkKdXP13cZMNahsU27pBbfYNf4QL2j0MJ66SMuoG92GKlLNX70ATe4_qRdSui3AWmLvoUe4zUFGrAPPnZY708OC5-xiefk1ME64ugvh-T1bvYyfcjmT_eP05t5ZjlXKtMCUYFy3Dqm3WICUHMl61oqJQEKzXWegys4WgUJYrlkoJkRNhUOEeSQXB53u-Dftxj7auW3IT0RK8kmOhcm50Wi2JFKwv4Bzqq9xepgsdpbrI4WK6nkL5YPbPI</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Abdouni, Samir El</creator><creator>van den Bosch, GE</creator><creator>van Rosse, F</creator><creator>Simons, SHP</creator><creator>Flint, RB</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20240801</creationdate><title>35 Prescribing behavior of analgosedatives for extremely premature neonates: a retrospective analysis</title><author>Abdouni, Samir El ; van den Bosch, GE ; van Rosse, F ; Simons, SHP ; Flint, RB</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1155-62ee5a5f1bf06fd8aac153cc3553aa761644af71eb5af1b0430a6092beb5feea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Analgesics</topic><topic>Fentanyl</topic><topic>I) Posters</topic><topic>Morphine</topic><topic>Newborn babies</topic><topic>Pediatrics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdouni, Samir El</creatorcontrib><creatorcontrib>van den Bosch, GE</creatorcontrib><creatorcontrib>van Rosse, F</creatorcontrib><creatorcontrib>Simons, SHP</creatorcontrib><creatorcontrib>Flint, RB</creatorcontrib><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>BMJ paediatrics open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Abdouni, Samir El</au><au>van den Bosch, GE</au><au>van Rosse, F</au><au>Simons, SHP</au><au>Flint, RB</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>35 Prescribing behavior of analgosedatives for extremely premature neonates: a retrospective analysis</atitle><jtitle>BMJ paediatrics open</jtitle><stitle>bmjpo</stitle><stitle>BMJ Paediatrics Open</stitle><date>2024-08-01</date><risdate>2024</risdate><volume>8</volume><issue>Suppl 6</issue><spage>A17</spage><epage>A17</epage><pages>A17-A17</pages><eissn>2399-9772</eissn><abstract>IntroductionManaging pain in extremely premature (EP) neonates is complex, and protocols at institutions often lack tailored advice for different indications or patient characteristics, increasing the risk of inadequate pain management. This study aims to examine clinician prescribing behavior, identify areas for improvement, and suggest modifications to existing protocols, which enables the improvement of analgosedative therapy for EP neonates.MethodologyIn this single center, retrospective study, we analyzed data from all EP neonates admitted to our NICU between 2017 and 2021, comparing baseline characteristics and drug administration data.ResultsOf the 2633 neonates admitted to the NICU, 10.2% (n=268) was EP at the time of admission. Of these, 53.4% (n=143) received analgosedative therapy. ‘Pain’ was the most common therapeutic indication (51.8%). Morphine, fentanyl, and acetaminophen were prescribed to more than half of the patients. Over 90% of patients received their analgosedative drugs exclusively intravenously (IV). Morphine and midazolam were mainly administered via continuous infusion, while fentanyl and acetaminophen were mostly given as bolus. During the initiation of continuous infusion, loading doses were administered for morphine and midazolam in 67.6% and 58.6% of cases, respectively. At dose escalation, these percentages decreased to 39.8% and 33.3% for morphine and midazolam, respectively. Morphine continuous infusion patients who always received a loading dose required a lower median dosage at 24 hours (5.0 mg/kg/hr) than those who didn’t (11.0 mg/kg/hr). This trend was not observed for midazolam (see table 1).ConclusionThe observed higher dosages required by EP neonates who did not receive a loading dose highlights the need for a critical evaluation of the use of loading doses during the initiation and dose escalation of continuous infusions, with the aim of reducing pain in this vulnerable population.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd</pub><doi>10.1136/bmjpo-2024-ESDPPP.35</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier EISSN: 2399-9772
ispartof BMJ paediatrics open, 2024-08, Vol.8 (Suppl 6), p.A17-A17
issn 2399-9772
language eng
recordid cdi_proquest_journals_3086429417
source BMJ Open Access Journals
subjects Analgesics
Fentanyl
I) Posters
Morphine
Newborn babies
Pediatrics
title 35 Prescribing behavior of analgosedatives for extremely premature neonates: a retrospective analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T00%3A18%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_9YT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=35%E2%80%85Prescribing%20behavior%20of%20analgosedatives%20for%20extremely%20premature%20neonates:%20a%20retrospective%20analysis&rft.jtitle=BMJ%20paediatrics%20open&rft.au=Abdouni,%20Samir%20El&rft.date=2024-08-01&rft.volume=8&rft.issue=Suppl%206&rft.spage=A17&rft.epage=A17&rft.pages=A17-A17&rft.eissn=2399-9772&rft_id=info:doi/10.1136/bmjpo-2024-ESDPPP.35&rft_dat=%3Cproquest_9YT%3E3086429417%3C/proquest_9YT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1155-62ee5a5f1bf06fd8aac153cc3553aa761644af71eb5af1b0430a6092beb5feea3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3086429417&rft_id=info:pmid/&rfr_iscdi=true